Novartis Piqray® Approved for Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer

(Source: MedicalResearch.com) PIK3CA is the most commonly mutated gene in HR+/HER2- breast cancer; … to develop flexible companion diagnostic solutions for Piqray that utilize both tumor ..